Literature DB >> 8685219

Low-grade transitional cell carcinoma of the urinary bladder: application of select cytologic criteria to improve diagnostic accuracy [corrected].

S S Raab1, D D Slagel, C S Jensen, M W Teague, V H Savell, D Ozkutlu, J C Lenel, M B Cohen.   

Abstract

The cytologic diagnosis of low-grade transitional cell carcinoma of the bladder is difficult, and the reported sensitivity of a positive diagnosis ranges from 0 to 73%. Using regression analysis, our laboratory previously reported the criteria of increased nuclear/cytoplasmic ratios, irregular nuclear membranes, and cytoplasmic homogeneity as indicative of low-grade transitional cell carcinoma. To examine the validity of these criteria, six observers examined 88 bladder-wash specimens (39 transitional cell carcinomas and 49 benign) and, using the selected criteria, graded each wash for the probability of malignancy. Diagnostic accuracy was measured using the receiver operating characteristic curve and the likelihood ratio. Overall observer accuracy was 76%, the sensitivity of a definitive negative diagnosis was 82%, and the specificity of a definitive positive diagnosis was 96%. We conclude that key cytologic criteria can be learned and effectively applied with high accuracy. Observer variation in diagnostic categories might reflect different confidence levels and probabilities of transitional cell carcinoma.

Entities:  

Mesh:

Year:  1996        PMID: 8685219

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  2 in total

1.  Diagnostic significance of atypical category in the voided urine samples: A retrospective study in a tertiary care center.

Authors:  Ghadeer A Mokhtar; Mohamed Al-Dousari; Doaa Al-Ghamedi
Journal:  Urol Ann       Date:  2010-09

2.  Circulating miRNA panels for specific and early detection in bladder cancer.

Authors:  Wataru Usuba; Fumihiko Urabe; Yusuke Yamamoto; Juntaro Matsuzaki; Hideo Sasaki; Makiko Ichikawa; Satoko Takizawa; Yoshiaki Aoki; Shumpei Niida; Ken Kato; Shin Egawa; Tatsuya Chikaraishi; Hiroyuki Fujimoto; Takahiro Ochiya
Journal:  Cancer Sci       Date:  2018-12-12       Impact factor: 6.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.